Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACIP Prevenar Coverage Recommendation Includes Prioritization Plan

Executive Summary

The Advisory Committee on Immunization Practices' coverage recommendation for Wyeth-Lederle's pending 7-valent pneumococcal conjugate vaccine Prevenar includes a prioritization plan to direct use of the product in the face of fiscal or supply limitations.

You may also be interested in...



Wyeth To Seek Prevenar Otitis Media Indication In Future Submission

Wyeth-Lederle plans to seek an indication for its pneumococcal conjugate vaccine Prevenar for the prevention of otitis media in a future submission to FDA.

Wyeth To Seek Prevenar Otitis Media Indication In Future Submission

Wyeth-Lederle plans to seek an indication for its pneumococcal conjugate vaccine Prevenar for the prevention of otitis media in a future submission to FDA.

Wyeth Withdraws RotaShield Ahead Of Rotavirus Season And ACIP Review

Wyeth-Lederle Vaccines is withdrawing the RotaShield rotavirus vaccine because recently gathered epidemiological data continue to suggest links to intussusception.

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel